GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Cyclically Adjusted PS Ratio

Haemonetics (Haemonetics) Cyclically Adjusted PS Ratio : 4.10 (As of Apr. 30, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Haemonetics Cyclically Adjusted PS Ratio?

As of today (2024-04-30), Haemonetics's current share price is $91.50. Haemonetics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $22.32. Haemonetics's Cyclically Adjusted PS Ratio for today is 4.10.

The historical rank and industry rank for Haemonetics's Cyclically Adjusted PS Ratio or its related term are showing as below:

HAE' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.78   Med: 3.44   Max: 7.77
Current: 4.08

During the past years, Haemonetics's highest Cyclically Adjusted PS Ratio was 7.77. The lowest was 1.78. And the median was 3.44.

HAE's Cyclically Adjusted PS Ratio is ranked worse than
66.02% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 2.12 vs HAE: 4.08

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Haemonetics's adjusted revenue per share data for the three months ended in Dec. 2023 was $6.536. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $22.32 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Haemonetics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Haemonetics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Cyclically Adjusted PS Ratio Chart

Haemonetics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.98 5.45 5.87 3.05 3.79

Haemonetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.66 3.79 3.85 4.01 3.83

Competitive Comparison of Haemonetics's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, Haemonetics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Haemonetics's Cyclically Adjusted PS Ratio falls into.



Haemonetics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Haemonetics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=91.50/22.32
=4.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Haemonetics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=6.536/129.4194*129.4194
=6.536

Current CPI (Dec. 2023) = 129.4194.

Haemonetics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 4.583 99.695 5.949
201406 4.339 100.560 5.584
201409 4.383 100.428 5.648
201412 4.461 99.070 5.828
201503 4.332 99.621 5.628
201506 4.155 100.684 5.341
201509 4.292 100.392 5.533
201512 4.600 99.792 5.966
201603 4.765 100.470 6.138
201606 4.115 101.688 5.237
201609 4.260 101.861 5.413
201612 4.373 101.863 5.556
201703 4.387 102.862 5.520
201706 3.994 103.349 5.002
201709 4.254 104.136 5.287
201712 4.408 104.011 5.485
201803 4.313 105.290 5.301
201806 4.400 106.317 5.356
201809 4.546 106.507 5.524
201812 4.683 105.998 5.718
201903 4.774 107.251 5.761
201906 4.675 108.070 5.599
201909 4.853 108.329 5.798
201912 5.015 108.420 5.986
202003 4.651 108.902 5.527
202006 3.816 108.767 4.541
202009 4.100 109.815 4.832
202012 4.680 109.897 5.511
202103 4.372 111.754 5.063
202106 4.486 114.631 5.065
202109 4.662 115.734 5.213
202112 5.059 117.630 5.566
202203 5.161 121.301 5.506
202206 5.059 125.017 5.237
202209 5.770 125.227 5.963
202212 5.961 125.222 6.161
202303 5.943 127.348 6.040
202306 6.064 128.729 6.097
202309 6.191 129.860 6.170
202312 6.536 129.419 6.536

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Haemonetics  (NYSE:HAE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Haemonetics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Haemonetics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Haemonetics (Haemonetics) Business Description

Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Executives
Stewart W Strong officer: President, Global Hospital C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni officer: EVP, Chief Technology Officer HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant director 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens officer: EVP, Global Manufacturing HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil officer: EVP and General Counsel HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell officer: VP, Chief Accounting Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin officer: President, Global Plasma & BC C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller officer: SVP, Human Resources C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll director PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein officer: VP, Corporate Controller HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon, director, officer: President & CEO HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca officer: EVP, Chief Financial Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr. officer: EVP, Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson director 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277